New immune therapy combo targets Tough-to-Treat blood cancer
NCT ID NCT06357676
Summary
This study is testing a new three-drug combination (glofitamab, ibrutinib, and obinutuzumab) for people with untreated mantle cell lymphoma (MCL), a type of blood cancer. It is for patients aged 65 and older, or younger adults with high-risk features. The main goals are to see if the treatment is safe and effective at controlling the cancer.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MANTLE CELL LYMPHOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
OHSU Knight Cancer Institute
RECRUITINGPortland, Oregon, 97239, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.